compound-10

NFAT:AP-1 inhibitor-10 is a novel inhibitor of the NFAT:AP-1:DNA interaction on the ARRE-2 element, binding to DNA in a sequence-selective manner and inhibiting the transcription of the Il2 gene and several other cyclosporin A-sensitive cytokine genes important for the effector immune response.

Compound 1245816-10-7, with CAS No. 1245816-10-7, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound 1245816-10-7 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

MINA53 inhibitor (Compound 10) is an inhibitor of MINA53.

Terbogrel is an oral thromboxane A2 receptor antagonist (IC50 is about 10 nM) and thromboxane A2 synthase inhibitor (IC50 is about 10 nM). Terbogrel is an antiplatelet compound that inhibits platelet aggregation and is a potential compound for the prevention of blood clots.

NO-prednisolone (NCX-1015) is a compound that effectively stimulates the production of IL-10 in vivo. It is a Prednisolone derivative that releases nitric oxide (NO).

SU11652 is an effective and competitive receptor tyrosine kinase (RTK) inhibitor, including VEGFR, FGFR, PDGFR, and Kit. SU11652 disrupts the function of all forms of mutant Kit and may be used in the study of cancers involving Kit mutations.

10-FTHF is a donor of formyl groups in anabolism used as a substrate in formyltransferase reactions, which is important in purine biosynthesis.This compound is unstable in powder form and other related salt forms are recommended.

IRAK4-IN-10 (compound 75) is a potent IRAK4 inhibitor (IC50 = 1.5 nM) that can block the MyD88-dependent signaling pathway and has research potential in inflammatory diseases, autoimmune diseases, and cancer.

Milataxel is an orally bioavailable taxane with potential antineoplastic activity. Upon oral administration, milataxel and its major active metabolite M-10 bind to and stabilize tubulin, resulting in the inhibition of microtubule depolymerization and cell division, cell cycle arrest in the G2 M phase, and the inhibition of tumor cell proliferation. Unlike other taxane compounds, milataxel appears to be a poor substrate for the multidrug resistance (MDR) membrane-associated P-glycoprotein (P-gp) efflux pump and may be useful for treating multidrug-resistant tumors. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus).This compound is unstable in powder form and other related salt forms are recommended.

Chlamydia pneumoniae-IN-1 (compound 55), a benzimidazole derivative, exhibits potent antibacterial activity, inhibiting 99% of C. pneumoniae growth at a concentration of 10 μM while maintaining 95% viability of host cells. It effectively inhibits the CV-6 strain of C. pneumoniae with a minimum inhibitory concentration (MIC) of 12.6 μM, demonstrating its antichlamydial efficacy [1].

DCZ3301 is a novel aryl-guanidino inhibitor.

Compound Fr13650, with CAS No. 155-10-2, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr13650 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr13677, with CAS No. 100704-10-7, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr13677 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr13747, with CAS No. 6966-10-5, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr13747 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr13852, with CAS No. 1572-10-7, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr13852 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr14024, with CAS No. 54454-10-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr14024 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr14136, with CAS No. 22236-10-8, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr14136 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound Fr14285, with CAS No. 6351-10-6, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound Fr14285 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound PDK0108, with CAS No. 1956-10-1, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound PDK0108 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound PDK0138, with CAS No. 2603-10-3, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound PDK0138 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound PDK0186, with CAS No. 334981-10-1, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound PDK0186 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Compound PDK0331, with CAS No. 675-10-5, is a fragment molecule that serves as an important scaffold for molecular linking, expansion, and modification. Compound PDK0331 provides a structural basis and research tool for the design and screening of novel drug candidates, and is commonly used in drug discovery, drug synthesis, and related research.

Irinotecan Hydrochloride (CPT-11 hydrochloride) is the hydrochloride salt of a semisynthetic derivative of camptothecin. Irinotecan, a prodrug, is converted to a biologically active metabolite 7-ethyl-10-hydroxy-camptothecin (SN-38) by a carboxylesterase-converting enzyme. One thousand-fold more potent than its parent compound irinotecan, SN-38 inhibits topoisomerase I activity by stabilizing the cleavable complex between topoisomerase I and DNA, resulting in DNA breaks that inhibit DNA replication and trigger apoptotic cell death. Because ongoing DNA synthesis is necessary for irinotecan to exert its cytotoxic effects, it is classified as an S-phase-specific agent.

(±)-10-Hydroxycamptothecin (Hydroxy Camptothecine) is an alkaloid isolated from the stem wood of the Chinese tree, Camptotheca acuminata. This compound selectively inhibits the nuclear enzyme DNA topoisomerase, type I. Several semisynthetic analogs of camptothecin have demonstrated antitumor activity.